GlassScriptPhysician profile
David Seil Kim
NPI 1184608259
$3,483.73
in general payments reported to CMS, 2019-2025
35 companies · $278 in 2025
The $278 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $799 · 2021: $203 · 2022: $939 · 2023: $716 · 2024: $182 · 2025: $278.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $771.74 | 2020-2022 | |
| Abbvie INC. | $642.20 | 2019-2023 | |
| Novo Nordisk INC | $331.16 | 2022-2025 | Wegovy |
| Mayne Pharma Commercial LLC | $279.00 | 2021-2025 | |
| Stryker Corporation | $199.37 | 2023 | Spy-Phi System, 1788, Xpress Ent Dilation System |
| Bayer Healthcare Pharmaceuticals INC. | $150.89 | 2019-2024 | |
| Exeltis, USA INC. | $115.98 | 2022-2025 | Slynd |
| Aspira Women'S Health INC | $97.13 | 2019-2023 | Ova1 |
| Baxter Healthcare | $74.24 | 2023 | Perclot, Tisseel |
| Duchesnay USA Incorporated | $73.71 | 2019 | |
| Astellas Pharma US INC | $58.23 | 2024 | Veozah |
| Boston Scientific Corporation | $47.46 | 2023-2024 | Orcapod |
| Pfizer INC. | $46.11 | 2023-2024 | |
| Myovant Sciences INC. | $45.65 | 2022 | |
| Sage Therapeutics, LLC | $45.54 | 2025 | Zurzuvae |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $45.54 | 2025 | Qelbree |
| Hologic Sales and Service, LLC | $42.76 | 2022-2024 | Aptima |
| Minerva Surgical, INC | $38.12 | 2023 | |
| Amag Pharmaceuticals, INC. | $34.52 | 2019-2020 | |
| Mycovia Pharmaceuticals, INC. | $34.37 | 2023 | Vivjoa |
| Lilly USA, LLC | $28.19 | 2025 | Mounjaro, Zepbound |
| Coopersurgical, INC. | $27.84 | 2019 | |
| Sumitomo Pharma America, INC. | $24.66 | 2025 | Gemtesa |
| Organon LLC | $24.63 | 2021 | |
| Daiichi Sankyo INC. | $24.11 | 2022 | |
| Scynexis, INC. | $22.36 | 2022 | |
| Channel Medsystems, INC. | $22.27 | 2022 | |
| Roche Diagnostics Corporation | $22.17 | 2019 | |
| Shield Therapeutics INC | $19.72 | 2023 | Accrufer |
| Agile Therapeutics, INC. | $19.53 | 2022 | |
| Allergan, INC. | $17.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.51 | 2020 | |
| Medicem INC. | $14.39 | 2022 | |
| Dysis Medical, INC. | $13.86 | 2020 | |
| Evofem Biosciences, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.